Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Shanghai Juncell Therapeutics Co., Ltd. (China)
Homepage:
juncell.com
Alternate names:
Juncell Therapeutics,
Shanghai Juncell Therapeutics,
Shanghai Juncell Therapeutics Co., Ltd.
ROR:
00zmdxp29
OpenAlex ID:
I4405267053
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
2024
·
Jing Guo
, Chunyan Wang
, et al.
·
BMC Medicine
·
20
A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer.
2024
·
Jing Guo
, Yuliang Wu
, et al.
·
Journal of Clinical Oncology
·
9
818TiP A pivotal phase II, randomized, controlled, open-label, trial (MIZAR-003) to assess the efficacy and safety of GC101 TIL, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, for patients with advanced anti-PD-1 refractory melanoma in later-line therapy
2025
·
J. Gu
, L. Si
, et al.
·
Annals of Oncology
·
2
A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma.
2026
·
Lu Si
, Yu Chen
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Abstract 5827: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
2025
·
Man Zhang
, Chen Huang
, et al.
·
Cancer Research
·
1
334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy
2026
·
Yanming Chen
, Wenjia Zhuang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
488 Phase I trial of GC101 TIL, a modified autologous tumor-infiltrating lymphocyte therapy, in advanced non-small cell lung cancer: long-term metabolic complete response in a patient with KRAS mutation
2026
·
Juan Li
, Wenjia Zhuang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti–PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial
2026
·
Jing Guo
, Yuliang Wu
, et al.
·
Clinical Cancer Research
PDF
Dual role of interleukin-2 in tumor-infiltrating lymphocyte therapy
2026
·
Lili Lu
, Wenjia Zhuang
, et al.
·
Clinical Cancer Bulletin
PDF
Abstract 3699: The "Preservation & Expansion" process: A key milestone for enhancing accessibility of autologous tumor-infiltrating lymphocyte therapy by enabling long-term cryopreservation of seed cells
2026
·
Zhou He
, Xingming Ma
, et al.
·
Cancer Research
Assessment of the severity of lower extremity peripheral arterial disease based on gastrocnemius surface electromyography and mechanomyography signals
2026
·
Wenxuan Sun
, Yanbin Guo
, et al.
·
Medical & Biological Engineering & Computing
219eTiP A phase Ib, open-label, single-arm trial of autologous natural tumor-infiltrating lymphocyte injection (GC101) in patients with advanced non-small cell lung cancer (NSCLC) (MIZAR-005)
2026
·
Z. Li
, Y. Zhang
, et al.
·
ESMO Open
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors
2026
·
Ying Zhang
, Sicheng Du
, et al.
·
Cancer Biology and Medicine
PDF
80P A phase I trial of optimized autologous tumor-infiltrating lymphocyte therapy without exogenous IL-2 in patients with advanced non-small cell lung cancer
2025
·
J. Li
, X. Chen
, et al.
·
Immuno-Oncology Technology
536 Phase 1 trial of tumor-infiltrating lymphocyte (TIL) therapy in recurrent glioblastoma: A single-center experience using cells derived from primary surgical specimens
2025
·
Yanming Chen
, Xingming Ma
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
63TiP A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial
2023
·
Q. Xu
, X. Guo
, et al.
·
Immuno-Oncology Technology
PDF
Show more works
View as search
Works count:
16
Citation count:
46
Year
Topic
Type